What Quantum BioPharma (NASDAQ: $QNTM) does

Quantum BioPharma Ltd. (NASDAQ: QNTM, formerly FSD Pharma Inc.) is a Toronto-based clinical-stage biopharmaceutical company developing therapies for neurodegenerative disorders, led by its investigational drug candidate Lucid-MS (LUCID-21-302), a patented new chemical entity designed to prevent and reverse myelin degradation in multiple sclerosis without immunosuppression. Lucid-MS is protected under patent WO2017027967A1 with exclusive worldwide rights and is supported by more than 11 years of R&D, peer-reviewed publications in Journal of Medicinal Chemistry and PNAS, and completed Phase 1 single-ascending-dose and multiple-ascending-dose studies in healthy volunteers. The company operates two distinct business lines: a pharmaceutical pipeline targeting the estimated US$34.8 billion (2025) global MS therapeutics market through traditional biopharma clinical development, and a consumer functional beverage, unbuzzd, launched in 2024 for rapid alcohol detoxification, backed by a published randomized clinical trial showing faster BrAC reduction than natural metabolism and mental alertness restoration in approximately 15–30 minutes.

Revenue mechanics are split across three streams. The pharmaceutical pipeline (Lucid-MS) has no current product revenue but future potential for one-time licensing or commercialization. The unbuzzd consumer beverage is sold direct-to-consumer through Amazon (ASIN B0DCLBH8S7) leveraging celebrity endorsements from Shark Tank's Kevin Harrington and former Celsius CEO Gerry David. The company also retains 19.84% ownership in spun-out Unbuzzd Wellness Inc., a 7% royalty on unbuzzd sales until cumulative royalties reach $250 million, and a 3% royalty in perpetuity thereafter, plus full rights to develop pharmaceutical and medical formulations (including the REKVRY hospital brand). The company maintains Australian subsidiaries (FSD Pharma Australia Pty Ltd. and Huge Biopharma Australia Pty Ltd.) for clinical operations and targets MS patients across North America, Western/Central Europe, China, Japan, and the UAE.

Name

Quantum BioPharma (NASDAQ: $QNTM)

Legal name

Quantum BioPharma Ltd.

Website

https://quantumbiopharma.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Quantum BioPharma (NASDAQ: QNTM) is a Toronto-based clinical-stage biopharmaceutical company developing Lucid-MS, a patented neuroprotective drug candidate for multiple sclerosis, while holding equity and royalty rights in spun-off Unbuzzd Wellness Inc. for a consumer alcohol-recovery beverage.

Ownership category

akta.pro rank

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Drug Development (Lucid-MS): Revenue potential from developing and commercializing Lucid-MS for multiple sclerosis treatment. The company has completed Phase 1 SAD/MAD human studies in healthy volunteers, evaluating safety, tolerability, and pharmacokinetic profile. The global MS therapeutics market is estimated at approximately US$34.8 billion in 2025, projected to reach US$66.8 billion by 2035.
2. unbuzzd Consumer Beverage Sales: Consumer functional beverage product targeting alcohol recovery market. Available for purchase through Amazon. The global hangover cure products market was valued at USD 1.56 billion in 2020, expected to expand at 14.6% CAGR from 2021 to 2028.
3. Royalty and Equity from Unbuzzd Wellness Inc. Spinoff: Quantum BioPharma retains 19.84% ownership interest in spun-out Unbuzzd Wellness Inc., plus 7% royalty on sales until cumulative royalty payments reach $250 million, then 3% royalty in perpetuity thereafter. Company also retains full rights to develop related pharmaceutical and medical formulations.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Quantum BioPharma is a clinical-stage biopharmaceutical company developing Lucid-MS, a patented New Chemical Entity (Lucid-21-302) for multiple sclerosis treatment by preventing and reversing myelin degradation without immunosuppression. The company also created unbuzzd, a science-backed functional beverage for rapid alcohol recovery, which has been spun out into Unbuzzd Wellness Inc. while Quantum BioPharma retains 19.84% ownership and royalty rights. A hospital formulation variant called REKVRY is also in development for emergency room settings.

Product overview

Quantum BioPharma is a biopharmaceutical company developing two distinct product lines: Lucid-MS (a patented new chemical entity for multiple sclerosis treatment targeting myelin protection and remyelination) and unbuzzd (a consumer functional beverage for rapid alcohol detoxification). The company spun out unbuzzd consumer rights into Unbuzzd Wellness Inc. while retaining 19.84% ownership and royalty rights. Lucid-MS has completed Phase 1 clinical trials, while unbuzzd launched in 2024 and is available on Amazon.

Differentiator

Problem solved

Functional benefit

Brands

• Lucid-MS: Patented neuroprotective compound being developed for multiple sclerosis treatment - a new chemical entity designed to prevent and reverse myelin degradation
• unbuzzd
• REKVRY

Products and services

• Lucid-MS Lucid-MS (Lucid-21-302) is a patented New Chemical Entity being developed as a neuroprotective compound for multiple sclerosis (MS) treatment. In preclinical models, it has demonstrated the ability to prevent and reverse myelin degradation without suppressing the immune system, and accelerate functional recovery in mouse models of MS. Phase 1 SAD/MAD human studies in healthy volunteers have been completed.
• unbuzzd unbuzzd is a science-backed functional beverage designed to help people feel more refreshed and balanced after drinking alcohol by supporting mental alertness and liver function. The proprietary formulation of vitamins and minerals has clinical trial evidence demonstrating faster reduction of Breath Alcohol Concentration (BrAC) than natural body metabolism, with mental alertness restoration in approximately 15-30 minutes on average. Available to consumers via Amazon e-commerce.
• REKVRY REKVRY is a hospital-market formulation of Quantum BioPharma's ethanol-eliminating technology targeting emergency room and healthcare settings for treatment of alcohol-related emergencies. It is designed to reduce costs and burden on healthcare resources and staff treating alcohol-intoxicated patients.

Quantifiable outcome

• Phase 1 SAD/MAD human studies completed for Lucid-MS
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Unbuzzd Wellness Inc.coreStrategic or Co-development PartnerSpin-off company for unbuzzd consumer beverage brand. Quantum BioPharma retains 19.84% ownership interest, 7% royalty on sales until cumulative royalty payments reach $250 million, and 3% royalty in perpetuity thereafter. Quantum BioPharma also retains full rights to develop related pharmaceutical and medical formulations.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Annovis Bio: Annovis Bio is a small-cap clinical-stage biopharma developing buntanetap for neurodegenerative diseases including early Alzheimer's and Parkinson's. It is comparable as a small-cap neuro-focused drug developer with similar capital constraints and clinical stage.
• Clene Nanomedicine: Clene Nanomedicine is developing CNM-Au8 for MS and other neurodegenerative diseases, with a similar small-cap, clinical-stage profile to Quantum BioPharma. Both target remyelination/neuroprotection in MS, making Clene a directly comparable emerging peer.

Broad incumbents

• Sanofi: Sanofi markets Aubagio (teriflunomide) and Lemtrada (alemtuzumab) for MS, and has been actively developing next-generation MS therapies. It is a relevant large-cap incumbent competing in the same MS therapeutics space.
• Novartis: Novartis markets Gilenya and Kesimpta for MS, both significant contributors to its neuroscience franchise. Comparable to Roche and Sanofi as a broad biopharma incumbent with established MS commercial presence.
• Roche: Roche markets Ocrevus (ocrelizumab), the leading high-efficacy MS therapy with over $6B in annual sales. As a top-3 MS therapeutics player, it represents the scale of competition Lucid-MS would face upon commercialization.
• Biogen: Biogen is the leading MS-focused biopharmaceutical company with an established MS franchise including Tysabri, Avonex, and Plegridy. It is the most direct large-cap incumbent in the MS therapeutics market where Lucid-MS competes, with deep commercial infrastructure and MS KOL relationships.
• Teva Pharmaceutical: Teva markets Copaxone (glatiramer acetate), historically one of the highest-revenue MS therapies. Its generic competition and biosimilar exposure make it a relevant comparable on MS market dynamics and pricing pressure.

Direct peers

• TG Therapeutics: TG Therapeutics is a clinical and commercial-stage biopharma with Briumvi (ublituximab) approved for relapsing MS. As a smaller, MS-focused biopharma, it is closely comparable to Quantum BioPharma in therapeutic focus and company stage relative to large incumbents.
• Merck KGaA: Through its healthcare division (EMD Serono in the US), Merck KGaA markets Mavenclad (cladribine) for relapsing MS. It is a directly comparable mid-to-large incumbent in the MS therapeutics category.
• Celsius Holdings: Celsius Holdings is the functional beverage company where former CEO Gerry David drove a 35-fold market cap increase. Quantum BioPharma's unbuzzd spinoff shares executive leadership (Gerry David, John Duffy from Coca-Cola) with Celsius, making it the closest comparable for the consumer beverage side of the business.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/QuantumBioPharma
• YouTubeyoutube.com/@quantumbiopharma
• Facebookfacebook.com/QuantumBioPharma
• LinkedInlinkedin.com/company/quantumbiopharma
• Instagraminstagram.com/quantumbiopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quantum BioPharma (NASDAQ: $QNTM)